Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Paul Szabolcs
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07284641CT.gov Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD) | — | Recruiting | — | — | — |
NCT01821781CT.gov Immune Disorder HSCT Protocol | — | Active Not Recruiting | — | — | — |
NCT01652092CT.gov Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Chronic Granulomatous Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Fludarabine (this asset) | Paul Szabolcs | P2 | CCC · 53 |
| Thiotepa | University of Florida | P2 | BB |
| Cyclophosphamide | Roswell Park Cancer Institute | P2 | CCC |
| Alemtuzumab | Paul Szabolcs | P2 | CCC |
| Melphalan | Paul Szabolcs | P2 | CCC |
| Anti-Human T-Lymphocyte Immunoglobulin, Rabbit | Paul Szabolcs | P2 | CCC |
| cd3/cd19 negative allogeneic hematopoietic stem cells | Paul Szabolcs | P1/2 | CCC |
| Abatacept Recombinant | Emory University | P1 | CC |
| Methotrexate | Fairview University Medical Center | N/A | D |
+6 more in the Chronic Granulomatous Disease cohort
Other indications for Fludarabine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult T-Cell Leukemia/Lymphoma | — | P2 | BBB · 76 |
| Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22) | — | P2 | BBB · 76 |
| Fanconi Anemia | — | P2/3 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Fludarabine in Chronic Granulomatous Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/fludarabine-chronic-granulomatous-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →